Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 15/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 7/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.37 |
| ▸ | S1PR5 | Q9H228 | 13/20 | 0.37 |
| ▸ | S1PR4 | O95977 | 11/20 | 0.37 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.37 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1967577 | 0.78 | S1PR1 (0.46) | S1PR1S1PR3S1PR5S1PR4 | |
| SCHEMBL2343395 | 0.78 | S1PR1 (0.46) | S1PR1S1PR3S1PR5S1PR4 | |
| SCHEMBL14822485 | 0.67 | OPRD1 (0.53) | SPHK1SPHK2 | |
| SCHEMBL3689270 | 0.67 | OPRD1 (0.53) | SPHK1SPHK2 | |
| SCHEMBL15481709 | 0.64 | OPRD1 (0.58) | SPHK1SPHK2CD274 | |
| SCHEMBL5221713 | 0.60 | SPHK1 (0.66) | SPHK1SPHK2 | |
| SCHEMBL5221700 | 0.60 | SPHK1 (0.66) | SPHK1SPHK2 | |
| SCHEMBL1312795 | 0.60 | S1PR1 (0.60) | S1PR1S1PR3SPHK1S1PR5S1PR4 | |
| SCHEMBL8408488 | 0.60 | GBA1 (0.48) | — | |
| SCHEMBL5227257 | 0.59 | SPHK1 (0.52) | SPHK1SPHK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207704-A1 | Novel Oxadiazole Compounds | ABBOTT LABORATORIES (US) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207704-A1 | Novel Oxadiazole Compounds | S1PR3, S1PR1, S1PR2 | S1PR1 2/4885S1PR3 1/4885MCHR1 899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.